Medtronic PLC vs Vaxcyte Inc. Common Stock — how do they compare? Medtronic PLC trades at $94.88 (market cap $118.97B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Medtronic PLC is far larger — about 11.3× Vaxcyte Inc. Common Stock's market cap, and Medtronic PLC pays a 3.1% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| MDT | PCVX | |
|---|---|---|
Market Cap | $118.97B | $10.51B |
Volume | 24,932,018 | 2,644,694 |
Sector | Health | Health |
52-Week High | $105.35 | $73.82 |
52-Week Low | $73.75 | $40.32 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | $138.31B | $9.14B |
Dividend Yield | 3.1% | — |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $94.23, up 2.5% with strong technical momentum near resistance at $95. The stock shows solid fundamentals with consistent earnings beats, 13.93% net margins, and a 49-year dividend growth streak. Recent CPT code approvals for medical devices and raised 2026 guidance signal operational strength. Technical indicators show bullish moving averages but RSI suggests potential overbought conditions near-term.
MDT offers value with 3.2% dividend yield and 7%+ revenue growth, though debt levels have risen to 31.1% of assets. Analyst consensus remains strongly bullish (61% buy ratings) with $97.73 price target. Key risks include execution of the MiniMed separation and medical device competition. The stock presents a balanced opportunity for income and growth investors.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →